Area of research
Genetics · Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include Glioma Diagnosis and Treatment, Advanced MRI Techniques and Applications, Diet and metabolism studies, and Medical Imaging Techniques and Applications.
BDNF levels in serum and CSF are associated with clinicoradiological characteristics of aggressive disease in MS patients
Optimized Long‐<scp>TE <sup>1</sup>H sLASER MR</scp> Spectroscopic Imaging at <scp>3T</scp> for Separate Quantification of Glutamate and Glutamine in Glioma
Amino acid metabolism in glioma: in vivo MR-spectroscopic detection of alanine as a potential biomarker of poor survival in glioma patients
<scp>2D <sup>1</sup>H sLASER</scp> Long‐<scp>TE</scp> and <scp>3D <sup>31</sup>P</scp> Chemical Shift Imaging at 3 T for Monitoring Fasting‐Induced Changes in Brain Tumor Tissue
Matching proposed clinical and MRI criteria of aggressive multiple sclerosis to serum and cerebrospinal fluid markers of neuroaxonal and glial injury
A fast protocol for multicenter and multiparametric quantitative MRI studies in brain tumor patients using vendor sequences
Machine-Learning-Aided Prediction of Brain Metastases Development in Non–Small-Cell Lung Cancers
Relevance of dedicated multiple sclerosis serum biomarkers in predicting contrast enhancement with gadolinium: Results from the <scp>REDUCE‐GAD</scp> trial
Serum neurofilament light chain is more strongly associated with T2 lesion volume than with number of T2 lesions in patients with multiple sclerosis
Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors
Short-term fasting in glioma patients: analysis of diet diaries and metabolic parameters of the ERGO2 trial
ERGO2: A Prospective, Randomized Trial of Calorie-Restricted Ketogenic Diet and Fasting in Addition to Reirradiation for Malignant Glioma
The ability to return to work: a patient-centered outcome parameter following glioma surgery
Lower Lactate Levels and Lower Intracellular pH in Patients with <i>IDH</i>-Mutant versus Wild-Type Gliomas
Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine
Intracellular pH measured by <sup>31</sup>P‐MR‐spectroscopy might predict site of progression in recurrent glioblastoma under antiangiogenic therapy
In vivo Metabolic Profiles as Determined by 31P and short TE 1H MR-Spectroscopy